Figure 2.
Figure 2. OS. Survival from time of initiation of AAT for SR-aGVHD in the entire cohort (n = 40) (A) and those who received ≥8 doses (solid) or <8 doses (hatched) (B).

OS. Survival from time of initiation of AAT for SR-aGVHD in the entire cohort (n = 40) (A) and those who received ≥8 doses (solid) or <8 doses (hatched) (B).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal